UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Timing of androgen deprivation monotherapy and combined treatments in castration-sensitive and castration-resistant prostate cancer: a narrative review

World journal of urology, 2020-03, Vol.38 (3), p.601-611

2020

Volltextzugriff (PDF)

Peri‐operative allogeneic blood transfusion does not adversely affect oncological outcomes after radical cystectomy for urinary bladder cancer: a propensity score‐weighted European multicentre study

BJU international, 2018-01, Vol.121 (1), p.101-110

2018

Volltextzugriff (PDF)

Prognostic role of FGFR alterations and FGFR mRNA expression in metastatic urothelial cancer treated with anti-PD(L1) inhibitors in first and second line setting

European urology open science (Online), 2020-07, Vol.19, p.e830

2020

Volltextzugriff (PDF)

Nierentransplantation in Harnableitungen

Urologe. Ausgabe A, 2020-01, Vol.59 (1), p.27-31

2020

Volltextzugriff (PDF)

Nebenwirkungsmanagement von Tyrosinkinaseinhibitoren in der Urologie: Arterielle Hypertonie

Urologe. Ausgabe A, 2016-07, Vol.55 (7), p.952-955

2016

Volltextzugriff (PDF)

Nebenwirkungsmanagement von Tyrosinkinaseinhibitoren in der Urologie: Gastrointestinale Nebenwirkungen

Urologe. Ausgabe A, 2016-06, Vol.55 (6), p.805-812

2016

Volltextzugriff (PDF)

Nebenwirkungsmanagement von Tyrosinkinaseinhibitoren in der Urologie: Fatigue und Hypothyreose

Urologe. Ausgabe A, 2016-05, Vol.55 (5), p.648-652

2016

Volltextzugriff (PDF)

Intrinsic molecular urothelial cancer subtypes remain stable during metastatic evolution

European urology, 2023-02, Vol.83, p.S1690-S1691

2023

Volltextzugriff (PDF)

A1171 - Intrinsic molecular urothelial cancer subtypes remain stable during metastatic evolution

European urology, 2023-02, Vol.83, p.S1690-S1691

2023

Volltextzugriff (PDF)

Heterogeneity-analysis of molecular subtypes of muscle-invasive bladder cancer and their precursor lesions in multiregion mapped whole-organ bladders

European urology, 2021-06, Vol.79, p.S644

2021

Volltextzugriff (PDF)

A0861 - Molecular characterization of upper urinary tract urothelial carcinoma and paired bladder cancer recurrences

European urology, 2024-03, Vol.85, p.S1896-S1897

2024

Volltextzugriff (PDF)

Molecular characterization of upper urinary tract urothelial carcinoma and paired bladder cancer recurrences

European urology, 2024-03, Vol.85, p.S1896-S1897

2024

Volltextzugriff (PDF)

Spatial immunephenotypes of distant metastases but not matched primary urothelial carcinomas predict response to immune checkpoint inhibition

European urology, 2023-02, Vol.83, p.S1686-S1687

2023

Volltextzugriff (PDF)

A1173 - Protein-based molecular subtypes associate with clinical-pathological characteristics in a multi-institutional cohort of upper tract urothelial carcinomas

European urology, 2023-02, Vol.83, p.S1693-S1694

2023

Volltextzugriff (PDF)

A1168 - Spatial immunephenotypes of distant metastases but not matched primary urothelial carcinomas predict response to immune checkpoint inhibition

European urology, 2023-02, Vol.83, p.S1686-S1687

2023

Volltextzugriff (PDF)

Protein-based molecular subtypes associate with clinical-pathological characteristics in a multi-institutional cohort of upper tract urothelial carcinomas

European urology, 2023-02, Vol.83, p.S1693-S1694

2023

Volltextzugriff (PDF)

Bladder tumor subtype commitment occurs in carcinoma in-situ driven by key signaling pathways including ECM remodeling

European urology, 2021-06, Vol.79, p.S640

2021

Volltextzugriff (PDF)

944P - Evaluation of different diagnostic methods for identification of FGFR alteration in advanced urothelial carcinomas: Proficiency results based on multiple RNA extraction kits and mutation detection methods

Annals of oncology, 2019-10, Vol.30, p.v380-v380

2019

Volltextzugriff (PDF)

Evaluation of different diagnostic methods for identification of FGFR alteration in advanced urothelial carcinomas: Proficiency results based on multiple RNA extraction kits and mutation detection methods

Annals of oncology, 2019-10, Vol.30, p.v380

2019

Volltextzugriff (PDF)

944PEvaluation of different diagnostic methods for identification of FGFR alteration in advanced urothelial carcinomas: Proficiency results based on multiple RNA extraction kits and mutation detection methods

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

Efficacy of anti-PD(L)1 treatment in patients with metastatic urothelial cancer based on mRNA- and protein- based PD-L1 determination: Results from the multicentric, retrospective FOsMIC trial

Annals of oncology, 2019-10, Vol.30, p.v378-v379

2019

Volltextzugriff (PDF)

933P - Prognostic role of FGFR Mutations and FGFR mRNA expression in metastatic urothelial cancer treated with anti-PD(L1) inhibitors in first and second-line setting

Annals of oncology, 2019-10, Vol.30, p.v375-v376

2019

Volltextzugriff (PDF)

941P - Efficacy of anti-PD(L)1 treatment in patients with metastatic urothelial cancer based on mRNA- and protein- based PD-L1 determination: Results from the multicentric, retrospective FOsMIC trial

Annals of oncology, 2019-10, Vol.30, p.v378-v379

2019

Volltextzugriff (PDF)

Prognostic role of FGFR Mutations and FGFR mRNA expression in metastatic urothelial cancer treated with anti-PD(L1) inhibitors in first and second-line setting

Annals of oncology, 2019-10, Vol.30, p.v375-v376

2019

Volltextzugriff (PDF)

Heterogeneity-analysis of molecular subtypes of muscle-invasive bladder cancer and their precursor lesions in multiregion mapped whole-organ bladders

Urologic oncology, 2020-12, Vol.38 (12), p.907-907

2020

Volltextzugriff (PDF)

1 – 25 von 209

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(161)
Mit Volltextzugriff
(174)

Publikationsform

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Timing of androgen deprivation monotherapy and combined treatments in castration-sensitive and castration-resistant prostate cancer: a narrative review

Peri‐operative allogeneic blood transfusion does not adversely affect oncological outcomes after radical cystectomy for urinary bladder cancer: a propensity score‐weighted European multicentre study

Prognostic role of FGFR alterations and FGFR mRNA expression in metastatic urothelial cancer treated with anti-PD(L1) inhibitors in first and second line setting

Nierentransplantation in Harnableitungen

Nebenwirkungsmanagement von Tyrosinkinaseinhibitoren in der Urologie: Arterielle Hypertonie

Nebenwirkungsmanagement von Tyrosinkinaseinhibitoren in der Urologie: Gastrointestinale Nebenwirkungen

Nebenwirkungsmanagement von Tyrosinkinaseinhibitoren in der Urologie: Fatigue und Hypothyreose

Intrinsic molecular urothelial cancer subtypes remain stable during metastatic evolution

A1171 - Intrinsic molecular urothelial cancer subtypes remain stable during metastatic evolution

Heterogeneity-analysis of molecular subtypes of muscle-invasive bladder cancer and their precursor lesions in multiregion mapped whole-organ bladders

A0861 - Molecular characterization of upper urinary tract urothelial carcinoma and paired bladder cancer recurrences

Molecular characterization of upper urinary tract urothelial carcinoma and paired bladder cancer recurrences

Spatial immunephenotypes of distant metastases but not matched primary urothelial carcinomas predict response to immune checkpoint inhibition

A1173 - Protein-based molecular subtypes associate with clinical-pathological characteristics in a multi-institutional cohort of upper tract urothelial carcinomas

A1168 - Spatial immunephenotypes of distant metastases but not matched primary urothelial carcinomas predict response to immune checkpoint inhibition

Protein-based molecular subtypes associate with clinical-pathological characteristics in a multi-institutional cohort of upper tract urothelial carcinomas

Bladder tumor subtype commitment occurs in carcinoma in-situ driven by key signaling pathways including ECM remodeling

944P - Evaluation of different diagnostic methods for identification of FGFR alteration in advanced urothelial carcinomas: Proficiency results based on multiple RNA extraction kits and mutation detection methods

Evaluation of different diagnostic methods for identification of FGFR alteration in advanced urothelial carcinomas: Proficiency results based on multiple RNA extraction kits and mutation detection methods

944PEvaluation of different diagnostic methods for identification of FGFR alteration in advanced urothelial carcinomas: Proficiency results based on multiple RNA extraction kits and mutation detection methods

Efficacy of anti-PD(L)1 treatment in patients with metastatic urothelial cancer based on mRNA- and protein- based PD-L1 determination: Results from the multicentric, retrospective FOsMIC trial

933P - Prognostic role of FGFR Mutations and FGFR mRNA expression in metastatic urothelial cancer treated with anti-PD(L1) inhibitors in first and second-line setting

941P - Efficacy of anti-PD(L)1 treatment in patients with metastatic urothelial cancer based on mRNA- and protein- based PD-L1 determination: Results from the multicentric, retrospective FOsMIC trial

Prognostic role of FGFR Mutations and FGFR mRNA expression in metastatic urothelial cancer treated with anti-PD(L1) inhibitors in first and second-line setting

Heterogeneity-analysis of molecular subtypes of muscle-invasive bladder cancer and their precursor lesions in multiregion mapped whole-organ bladders

Suchergebnisse filtern